Core Viewpoint - Exegenesis Bio Inc. (嘉因生物) is focused on gene therapy and oligonucleotide drugs, with a strong emphasis on innovative delivery systems and a diverse product pipeline aimed at addressing significant unmet clinical needs in both rare and common diseases [2][4]. Company Overview - Exegenesis Bio Inc. was established in 2019 and has developed advanced delivery vector technologies, positioning itself as a leader in the biopharmaceutical industry [2]. - The company has submitted its IPO application to the Hong Kong Stock Exchange, with CCB International acting as the sole sponsor [2]. Product Pipeline - The company’s core candidate product, EXG001-307, is a promising gene therapy for Spinal Muscular Atrophy (SMA) type 1, expected to be a best-in-class treatment [4][5]. - Other key candidates include EXG102-031, targeting wet Age-related Macular Degeneration (wAMD), and EXG202, aimed at treating retinal neovascular diseases, including wAMD and Diabetic Macular Edema (DME) [4][5]. - EXG001-307 is noted for its single-dose administration and its ability to minimize expression in peripheral tissues, addressing safety concerns associated with current gene therapies [4]. Market Potential - The global market for SMA treatments is projected to grow from $4.6401 billion in 2024 to $5.9319 billion by 2030, and further to $9.4469 billion by 2035 [4]. - The market for retinal neovascular disease treatments is estimated to increase from $15.6 billion in 2024 to $29.5 billion by 2030, and to $55.8 billion by 2035 [5]. Investment and Funding - Exegenesis Bio has attracted investments from notable institutions such as Hillhouse Capital, Sequoia, and Temasek, among others [6]. - The net proceeds from the IPO are intended to fund the development of core products EXG001-307, EXG102-031, and EXG202, as well as to enhance technological capabilities and support general corporate purposes [6].

Company Overview - Exegenesis Bio has submitted a listing application to the Hong Kong Stock Exchange, with CCB International as the sole sponsor [1] - The company specializes in gene therapy and oligonucleotide drugs, possessing globally leading delivery vector technology according to Frost & Sullivan [1] - Exegenesis Bio has developed proprietary platforms AAVarta (AI-assisted AAV capsid evolution discovery platform) and SODA (silencing oligonucleotide design method) [1] Key Products - The core candidate product EXG001-307 (for SMA type 1) aims to be the best-in-class therapy for spinal muscular atrophy (SMA) type 1, having received IND approval from the National Medical Products Administration in June 2022 and completed Phase I/II clinical trials in China [1] - Key candidate products EXG102-031 (AAV gene therapy for wet age-related macular degeneration, wAMD) and EXG202 (AAV gene therapy for retinal neovascular diseases including wAMD) aim to overcome the limitations of existing anti-VEGF biologics [1] Market Potential - The global gene therapy market is projected to grow from approximately $2.8 billion in 2024 to $32 billion by 2035 [2] - The Chinese gene therapy market is expected to reach RMB 11.6 billion by 2035 [2] - The global SMA drug market is anticipated to increase from $4.6401 billion in 2024 to $9.4469 billion by 2035 [2] - The Chinese SMA drug market is projected to grow from RMB 550.9 million in 2024 to RMB 3.2945 billion by 2035 [2]

Core Business and Business Model - Exegenesis Bio Inc. focuses on gene therapy and oligonucleotide drug development, established in 2019, with headquarters in the Cayman Islands and operational entities in Hangzhou and Guangzhou, China. The company utilizes two core technology platforms: AAVarta and SODA, targeting rare and common diseases for innovative therapy development [1] - The company has 11 candidate products in development, including treatments for spinal muscular atrophy (SMA), wet age-related macular degeneration (wAMD), and Fabry disease. The core product EXG001-307 (for SMA type 1) is in Phase III clinical trials, while EXG102-031 (for wAMD) and EXG202 (for retinal neovascular diseases) are in Phase I/II [1] Revenue and Financial Performance - As of the first nine months of 2025, the company reported revenue of 1.299 million RMB, primarily from R&D services for overseas clients, indicating a lack of commercialized products and a revenue scale significantly below industry averages [2][3] - The net loss for the first nine months of 2025 reached 94.33 million RMB, continuing a trend of increasing losses primarily due to high R&D expenditures, which accounted for 87.3% of total operating expenses [2] - The gross margin for the first nine months of 2025 was only 10%, reflecting a weak profitability of the current business model, which relies heavily on R&D services rather than product sales [2] Customer and Supplier Concentration - The company’s revenue is entirely dependent on a single overseas client, resulting in a customer concentration of 100%, which poses a significant risk to business continuity [3][7] - The company has a high dependency on suppliers, with the top five suppliers accounting for 47.6% of procurement in the first nine months of 2025, indicating potential supply chain risks [8] Financial Challenges - As of September 2025, the company faced severe financial challenges, with net current liabilities of 1.632 billion RMB and a cash burn rate of approximately 70 million RMB per month, suggesting that existing cash reserves can only sustain operations for about 3.7 months [5][6] Competitive Landscape - Compared to peers, Exegenesis Bio's R&D efficiency is lower, with 145 million RMB spent in 2024 to advance only one Phase III and two Phase I/II products, while competitors have achieved more significant milestones with higher investments [6] - In the SMA treatment market, competition is intense, with Novartis's Zolgensma already approved globally, and domestic competitors advancing more rapidly in clinical trials [6][10] Management and Governance - The company is controlled by a founding team holding 31.16% of voting rights, which may lead to a lack of checks and balances in decision-making due to concentrated ownership [9] - The management team has extensive experience in gene therapy, but there is a lack of transparency regarding their compensation and incentive mechanisms [9] Regulatory and Commercialization Risks - The company faces multiple risks related to clinical development, regulatory approval, and commercialization, particularly with the core product's clinical data showing inferior efficacy compared to competitors [10][11][12] - As a biotechnology company under Chapter 18A, it must meet ongoing R&D requirements post-listing, with potential delisting risks if core product development fails [11] - The company has not yet established a sales team, raising concerns about its commercialization capabilities in a competitive market [12]

Company Overview - Exegenesis Bio Inc. is a biopharmaceutical company focused on gene therapy and oligonucleotide drugs, possessing leading delivery vector technology according to Frost & Sullivan [3] - The company has developed a diverse and scalable product pipeline, including its core candidate EXG001-307 for SMA type 1, and two key candidates EXG102-031 and EXG202 for age-related macular degeneration and retinal vascular diseases respectively [3][4] Product Development - EXG001-307 is designed to reduce systemic exposure risks and enhance overall safety while restoring SMN physiological balance in motor neurons, addressing limitations of current SMA gene therapies [4] - EXG001-307 received IND approval from the National Medical Products Administration in June 2022 and has completed a Phase I/II clinical trial in China [4] - EXG102-031 and EXG202 aim to overcome limitations of existing anti-VEGF biologics, such as short half-lives and incomplete pathway inhibition [4] Financial Information - The company reported no revenue for the fiscal year ending December 31, 2024, and generated revenue of RMB 1.299 million from R&D services for a foreign client in the nine months ending September 30, 2025 [5] - R&D expenses were RMB 145 million for the fiscal year 2024 and RMB 81.64 million for the nine months ending September 30, 2025 [6] Industry Overview - The global gene therapy market is projected to grow from approximately USD 2.8 billion in 2024 to USD 12.6 billion by 2030, with a compound annual growth rate (CAGR) of 28.4% [8] - The Chinese gene therapy market is expected to grow from approximately RMB 0 billion in 2024 to RMB 2.3 billion by 2030, with a CAGR of 123.0% [11] SMA Market Insights - The global SMA drug market is expected to grow from USD 3.0308 billion in 2020 to USD 4.6401 billion in 2024, with a CAGR of 11.2% [14] - The Chinese SMA drug market is projected to increase from RMB 0.070 billion in 2020 to RMB 0.5509 billion in 2024, with a CAGR of 67.5% [17]

Company Overview - Exegenesis Bio Inc. is a biopharmaceutical company focused on gene therapy and oligonucleotide drugs, possessing leading delivery vector technology according to Frost & Sullivan [3] - The company was established in 2019 and has developed a diverse and scalable product pipeline, including its core candidate EXG001-307 for SMA type 1 and two key candidates EXG102-031 and EXG202 for age-related macular degeneration and retinal vascular diseases [3][4] Product Pipeline - The core candidate EXG001-307 is designed to reduce systemic exposure risks and enhance overall safety while restoring SMN physiological balance in motor neurons, addressing limitations of current SMA gene therapies [4] - EXG001-307 received IND approval from the National Medical Products Administration in June 2022 and has completed a Phase I/II clinical trial in China [4] - EXG102-031 and EXG202 are single-dose AAV-based gene therapies aimed at overcoming limitations of existing anti-VEGF biologics [4] Financial Information - The company reported no revenue during the fiscal year ending December 31, 2024, and generated revenue of RMB 1.299 million from R&D services for an overseas client in the nine months ending September 30, 2025 [5] - R&D expenses were RMB 145 million for the fiscal year 2024 and RMB 81.64 million for the nine months ending September 30, 2025 [6] Industry Overview - The global gene therapy market is projected to grow from approximately USD 2.8 billion in 2024 to USD 12.6 billion by 2030, with a compound annual growth rate (CAGR) of 28.4% [8] - The Chinese gene therapy market is expected to grow from RMB 0 in 2024 to RMB 2.3 billion by 2030, with a CAGR of 123.0% [11] SMA Market Insights - The global SMA drug market is anticipated to grow from USD 3.0308 billion in 2020 to USD 4.6401 billion in 2024, with a CAGR of 11.2% [14] - The Chinese SMA drug market is projected to increase from RMB 0.070 billion in 2020 to RMB 0.5509 billion in 2024, with a CAGR of 67.5% [17]